Total Funding
42
Total FundingPost-IPO Equity raised
Growth Score
pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
13854
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
- Richard Fisher: Chief Scientific OfficerPast Role: Proclara Biosciences, Chief Scientific Officer
- Petra Kaufmann: Chief Medical OfficerPast Role: Affinia Therapeutics, Chief Medical Officer
About the Company
Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.
Women Founded
